Zai Lab FY2025 EPS Estimate Decreased by Cantor Fitzgerald

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) – Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for shares of Zai Lab in a report issued on Monday, June 23rd. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($0.94) per share for the year, down from their prior estimate of ($0.82). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zai Lab’s current full-year earnings is ($2.58) per share. Cantor Fitzgerald also issued estimates for Zai Lab’s FY2026 earnings at $0.27 EPS.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. upped their price target on Zai Lab from $44.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, March 13th. Scotiabank initiated coverage on Zai Lab in a research note on Friday, March 7th. They set a “sector outperform” rating and a $55.00 price target on the stock. Finally, Bank of America reaffirmed a “neutral” rating and set a $36.10 price target (up from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd.

Zai Lab Trading Down 2.1%

NASDAQ ZLAB opened at $36.19 on Wednesday. The business’s 50-day moving average price is $33.35 and its two-hundred day moving average price is $31.02. Zai Lab has a 12 month low of $16.01 and a 12 month high of $44.34. The firm has a market capitalization of $3.99 billion, a PE ratio of -14.53 and a beta of 0.96.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.05. Zai Lab had a negative return on equity of 33.35% and a negative net margin of 60.26%. The firm had revenue of $106.49 million for the quarter, compared to analyst estimates of $118.40 million.

Institutional Investors Weigh In On Zai Lab

Several institutional investors have recently made changes to their positions in the stock. FMR LLC raised its position in shares of Zai Lab by 749.1% in the fourth quarter. FMR LLC now owns 5,475,505 shares of the company’s stock worth $143,403,000 after buying an additional 4,830,646 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Zai Lab by 63.6% during the 1st quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company’s stock valued at $104,257,000 after purchasing an additional 1,121,856 shares during the period. RTW Investments LP purchased a new position in Zai Lab during the 4th quarter valued at about $65,714,000. Price T Rowe Associates Inc. MD increased its holdings in Zai Lab by 30.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,354,025 shares of the company’s stock valued at $61,653,000 after purchasing an additional 548,378 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Zai Lab by 46,222.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company’s stock worth $77,058,000 after acquiring an additional 2,127,598 shares in the last quarter. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Insider Activity

In other Zai Lab news, insider Frazor Titus Edmondson III sold 4,369 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $35.89, for a total transaction of $156,803.41. Following the sale, the insider now owns 27,217 shares in the company, valued at $976,818.13. This represents a 13.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Ying Du sold 5,808 shares of the stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $35.89, for a total value of $208,449.12. Following the sale, the chief executive officer now owns 476,046 shares in the company, valued at approximately $17,085,290.94. This represents a 1.21% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 141,021 shares of company stock valued at $4,257,755 over the last three months. Corporate insiders own 4.96% of the company’s stock.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.